SOURCE: Generex Biotechnology Corporation

March 05, 2007 07:15 ET

38th NAACP Image Awards Feature Generex Biotechnology's Pipeline of Diabetes Products

TORONTO -- (MARKET WIRE) -- March 5, 2007 -- Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that the Company participated in the 38th Image Awards of the National Association for the Advancement of Colored People held in Los Angeles, CA on Friday, March 2, 2007, where its pipeline of diabetes products were featured.

Diabetes is exploding in all corners of the world. Although every population is at risk, it is apparent that certain ethnic groups have a greater propensity for the development of Type-2 diabetes. In the Arab states in the gulf region, as much as 20% of the population is afflicted with diabetes. India and China also have an extremely high incidence of diabetes. In North America, African American, Hispanic, and Asian populations are twice as likely to develop diabetes as the Caucasian population.

Jackie Robinson, Ella Fitzgerald, Luther Vandross and countless other prominent African Americans have died prematurely because of diabetes and its complications. Today, such luminaries as Halle Berry and B.B. King are speaking out about this disease.

Generex participated in the 38th NAACP Image Awards to raise awareness of the threat of diabetes to the African American population and to highlight the prevention, diagnosis, and treatment of the disease. Proper management of diabetes is crucial to prevent cardiovascular disease, blindness, kidney failure, and limb loss. The Company introduced its pipeline of diabetes products including Generex Oral-lyn™, its proprietary oral insulin spray product, and Glucose RapidSpray™, its proprietary glucose spray product.

Established in 1967, at the height of the civil rights movement, the NAACP Image Awards is the United States' premier event to honor outstanding black actors, actresses, writers, producers and directors. Presented annually, the NAACP Image Awards are an exciting, star-studded salute to the best in entertainment. Honorees, presenters, and performers have included many of the major celebrities in America as well as international political figures and dignitaries.

The mission of the NAACP is to ensure the political, educational, social, and economic equality of rights of all persons and to eliminate racial hatred and racial discrimination.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Contact Information

  • For more information, please contact:

    For Generex:

    Shayne Gilliatt
    Generex
    800-391-6755 or 416-364-2551

    Andrew Hellman
    CEOcast, Inc.
    212-732-4300